Essilor Stellest glasses: FDA-approved lens aim to slow myopia progression - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA-Approved Essilor Stellest Lenses Designed to Mitigate Myopia Progression

  • By

  • Matthew Perrone

  • December 1, 2025

Share

Clinical Scorecard: FDA-Approved Essilor Stellest Lenses Designed to Mitigate Myopia Progression

At a Glance

CategoryDetail
ConditionMyopia (nearsightedness) in children
Key MechanismsLenses use 11 concentric rings with tiny raised dots to refocus light onto the retina, slowing eye elongation
Target PopulationChildren aged 6 to 12 years with myopia
Care SettingOphthalmology and optometry clinics

Key Highlights

  • Essilor Stellest lenses approved by FDA reduce myopia progression by 70% over two years in children aged 6-12
  • Lenses slow eye elongation by approximately 50%, potentially reducing long-term risks like retinal detachment and blindness
  • Glasses offer a non-contact lens alternative preferred by many parents and physicians for young children

Guideline-Based Recommendations

Diagnosis

  • Identify myopia in children through standard eye examinations
  • Consider age range 6-12 years for Essilor Stellest lens prescription

Management

  • Prescribe Essilor Stellest lenses to slow myopia progression in eligible children
  • Consider alternative FDA-approved options like MiSight contact lenses for children aged 8-12
  • Medicated eye drops are used off-label but not FDA-approved for myopia control

Monitoring & Follow-up

  • Monitor visual acuity and eye elongation regularly during treatment
  • Watch for visual disturbances such as halos around objects
  • Ongoing research and local data collection recommended to confirm efficacy in U.S. populations

Risks

  • No serious side effects reported in FDA studies
  • Some children may experience visual disturbances like halos
  • Long-term safety and effectiveness data in U.S. populations pending further studies

Patient & Prescribing Data

Children aged 6-12 years diagnosed with myopia

Lenses reduce myopia progression by 70% and eye elongation by 50% over two years; retail price approximately $450; expected insurance coverage for eligible children

Clinical Best Practices

  • Confirm myopia diagnosis and assess eligibility based on age
  • Discuss treatment options including Essilor Stellest lenses and MiSight contact lenses with families
  • Inform patients and caregivers about potential visual disturbances and monitor accordingly
  • Encourage participation in ongoing studies to gather U.S.-based efficacy and safety data
  • Consider patient and family preferences when choosing between glasses and contact lenses

References

Original Source(s)

Related Content